

## CURRICULUM VITAE

**Ronald Leo Paquette, M.D.**

### **PERSONAL INFORMATION**

**Office address:** Cedars-Sinai  
Blood and Marrow Transplant Program  
8700 Beverly Blvd, Suite AC1046-A  
Los Angeles, CA 90048  
**Office phone:** (310) 423-1160  
**Clinic FAX:** (310) 423-4646  
**email address:** ronald.paquette@cshs.org

### **EDUCATION AND TRAINING**

	<u>Degree or Training</u>	<u>Institution</u>
1976-80	BS, Microbiology	University of Notre Dame
1980-84	MD	The Ohio State University
1984-87	Internship, Residency	University of California, Los Angeles
1987-90	Fellowship (Heme/Onc)	University of California, Los Angeles

### **LICENSURE**

Medical Board of California: G 59889

### **BOARD CERTIFICATION**

9/88 Diplomate in Internal Medicine, American Board of Internal Medicine  
9/89 Diplomate in Medical Oncology, American Board of Internal Medicine

### **PROFESSIONAL EXPERIENCE**

7/90 - 6/92 Clinical Instructor, UCLA Department of Medicine  
7/92 - 12/98 Assistant Clinical Professor, UCLA Department of Medicine  
7/97 - 2/16 Medical Director, Stem Cell Processing Laboratory  
1/99 - 6/09 Associate Professor, UCLA Department of Medicine  
7/01 - 12/06 Associate Director, Hematopoietic Malignancies and Bone Marrow Transplantation Program Area of the Jonsson Comprehensive Cancer Center  
7/02 - 12/04 Medical Director, UCLA Umbilical Cord Blood Bank  
7/09 - 1/16 Clinical Professor, UCLA Department of Medicine  
2/16 - Present Staff Physician III, Cedars-Sinai Blood and Marrow Transplant Program

### **COMMITTEE SERVICE**

7/94 - 2/16 Morbidity and Mortality Peer Review Committee, UCLA Department of Medicine  
10/95 - 2/16 Institutional Review Board, UCLA

### **COMMUNITY SERVICE**

11/01- Present Medical Advisory Board, Aplastic Anemia & MDS International Foundation, Inc.

Annually Speaking for the Leukemia and Lymphoma Society

### **MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

5/95 - Present American Society of Hematology

### **EDITORIAL SERVICES**

Reviewer: *Blood, Leukemia Research*

## **CONSULTING ACTIVITIES**

12/8/05 Telik Inc.  
2/24/07 Alexion Pharmaceuticals  
12/7/07 Telik Inc.  
5/17/08 Bristol-Myers Squibb  
2/26/10 Novartis Pharmaceuticals  
5/26/11 Ariad Pharmaceuticals  
9/16/11 Novartis Pharmaceuticals  
9/24/11 Incyte Corp.  
6/9/12 Ariad Pharmaceuticals  
5-6/14 Astra Zeneca

## **RESEARCH GRANTS AND FELLOWSHIPS**

8/93-7/98 NIH Clinical Investigator K08 Award: "Myeloid-Specific Regulation of IgG Fc Receptor Type I"  
6/94-6/95 Aplastic Anemia Foundation of America New Research Award: "Mutations of Interleukin-1 and Stem Cell Factor Receptor Genes in Aplastic Anemia"  
7/98-6/99 University of California Cancer Research Coordinating Committee: "Cellular Immunotherapy for Chronic Leukemias"  
12/99-11/00 UCLA Jonsson Cancer Center Foundation: "Dendritic Cells in the Pathogenesis and Treatment of CML"  
7/00-6/05 Leukemia and Lymphoma Society of America: "Molecularly Targeted Therapy for CML"  
3/04-2/05 Stein Oppenheimer Award: "Dendritic Cell Therapy for Myeloid Leukemia"  
9/03-8/09 NIH. U54 Award Number: RR-03-008  
"Bone Marrow Failure Clinical Research Center"  
Purpose: Form a consortium of centers to improve treatment of the idiopathic bone marrow failure states  
\$ 813,672 annual direct costs  
Role: Co-Investigator (Effort: 15%)  
7/05-6/10 Leukemia and Lymphoma Society of America. Number: R7036-01  
"Molecularly Targeted Therapy for Leukemia"  
Purpose (Project 2): Conduct clinical trials of novel drugs in CML patients with imatinib resistance  
Amount: \$ 200,000 annual direct costs  
Role: Co-Investigator (Effort: 25%)

## **INVITED LECTURES AND PRESENTATIONS (1998-2012)**

2/26/98 Cancer Research Conference; UCLA. "Ex Vivo Expansion"  
4/2/98 San Gabriel Valley Medical Center. "Microcytic Hypochromic Anemia"  
6/25/98 Northridge Hospital Medical Center. "Approach to the Patient with Anemia"  
8/1/98 The Aplastic Anemia Foundation of America, Inc. Annual Patient Conference; San Diego, CA. "Current Status of Immunosuppressive Treatment and Research in Aplastic Anemia"  
3/9/99 Encino Tarzana Regional Medical Center. "Sickle Cell Anemia"  
4/22/99 Consensus Conference on the Treatment of Aplastic Anemia in Japan; Tokyo, Japan. "Effect of Stem Cell Factor in Patients with Aplastic Anemia"  
9/30/99 Johnson Cancer Center Research Conference; UCLA. "Ex Vivo Expansion of Hematopoietic Progenitor Cells"  
1/20/00 Sangstat Medical Corporation Retreat; Scottsdale, AZ. "Myelodysplastic Syndrome and Aplastic Anemia"  
4/28/00 International Conference on Haematopoietic Stem Cell Biology and Transplantation; Paris, France. "Clinical Experience with Ex Vivo Expanded Peripheral Blood Progenitor Cells"  
7/25/00 Amgen Inc; Thousand Oaks, CA. "Ex Vivo Expansion"  
9/18/00 Leukemia and Lymphoma Society Support Group; UCLA. "Chronic Leukemias"

12/2/00 ASH Meeting, San Francisco, CA. "Ex Vivo Expanded Unselected Peripheral Blood Progenitor Cells Reduce Post-Transplant Neutropenia, Thrombocytopenia, and Anemia in Breast Cancer Patients"

6/02/01 UCLA Clinical Oncology Network; Arrowhead, CA. "Clinical Trials of STI571 (Gleevec) in Chronic Myeloid Leukemia"

7/15/01 Novartis Physician Educational Meeting; Hollywood, CA. "Gleevec (STI571) Trials in Chronic Myeloid Leukemia"

9/10/01 Novartis 3T Meeting; Century City, CA. "Everything You Wanted to Know About CML but Were Afraid to Ask"

10/29/01 Laboratory Medicine Grand Rounds; UCLA. "Clinical Experience with Ex Vivo Expanded Peripheral Blood Progenitor Cells"

1/21/02 Novartis Retreat; Beverly Hills, CA. "Update on Gleevec"

1/31/02 UCLA Apheresis Conference; UCLA. "CML, Gleevec and Autologous Stem Cell Transplantation"

3/3/02 5<sup>th</sup> Quality of Life in Oncology; Pasedena, CA. "Diagnosis and Management of Aplastic Anemia and Myelodysplastic Syndrome"

3/26/02 Pediatric Hematology/Oncology Grand Rounds; UCLA. "Ex Vivo Expansion: From the Bench to the Bedside"

4/6/02 UCLA Update in Stem Cell Transplantation; UCLA. "Stem Cell Transplantation in the Post-Gleevec Era"

6/1/02 UCLA Clinical Oncology Network; Arrowhead, CA. "Tyrosine Kinase Inhibitors for Acute Myeloid Leukemia"

6/10/02 UCLA Leukemia Conference; UCLA. "Dendritic Cells in the Pathogenesis and Treatment of CML"

7/26/02 UCLA Housestaff Conference; UCLA. "Bone Marrow and Peripheral Blood Stem Cell Transplantation"

4/12/03 UCLA Clinical Oncology Network; Arrowhead, CA. "New Treatment Approaches for CML and AML"

5/13/03 JCCC Molecular and Cellular Biology Program Area; UCLA. "New Treatment Approaches for CML and AML"

8/1-2/03 The Aplastic Anemia & MDS International Foundation, Inc. Annual Patient & Family Conference; San Francisco, CA.  
 Medical Team Panel Discussion "Improving Doctor & Patient Relations", "How to Use Medical Information", "Aplastic Anemia, Myelodysplastic Syndrome and Paroxysmal Nocturnal Hemoglobinuria: How Are They Similar, Different, Related?"

10/28/03 Westwood VA Medical Center; Los Angeles, CA. "Targeted Therapy for Chronic Myeloid Leukemia"

3/19/04 Hematology/Oncology Grand Rounds; UCLA. "Update on Bone Marrow Failure"

5/23/04 UCLA Translational Oncology Network International; Lake Arrowhead, CA. "On Beyond Gleevec: New Targeted Therapies for Leukemia"

8/3/04 UCLA Housestaff Conference; UCLA. "Bone Marrow and Peripheral Blood Stem Cell Transplantation"

9/28/04 Meet the Doctor; UCLA Medical Center. "Myelodysplastic Syndrome"

10/5/04 Leukemia & Lymphoma Society Symposium; Los Angeles, CA. "Chronic Myelogenous Leukemia: Treatment Update"

5/16/05 ASCO Meeting; Orlando, FLA. "A Phase I Study of BMS-354825 in Patients with Imatinib-Resistant and Intolerant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML): Results from CA180002"

4/7-5/25/06 A series of 8 teleconferences for physicians and nurses. "Low-Risk Myelodysplastic Syndrome: Optimizing Treatment Strategies and Improving Patient Outcomes"

4/27/06 Meet the Doctor; UCLA Medical Center. "Myelodysplastic Syndrome"

6/23/06 Amgen Investigators Meeting; San Francisco, CA. "Myelodysplastic Syndromes: a 2006 Update of Aranesp Data"

8/7/06 Educational Dinner Series; Los Angeles, CA. "Monitoring Patient Response to Treatment in CML"

10/1/06 TORI Research Network Conference; Ventura, CA. "Novel Therapeutic Trials for Hematologic Malignancies"

10/17/06 Educational Dinner Series; Los Angeles, CA. "Update on CML Management"

10/19/06 CML Support Group Lecture, The Leukemia & Lymphoma Society – Orange County/Inland Empire Chapter; Orange, CA. "CML Update"

2/07/07 Leukemia Case Conference, UCLA. "A Case of Anemia and Thrombocytopenia: the Culprit is aT Large."

3/27/07 Lunch Teleconference. "Management Issues in CML"

3/29/07 Educational Dinner Series; Costa Mesa, CA. "Update on the Management of CML"

4/27/07 Hematology/Oncology Grand Rounds; UCLA Medical Center. "Update on CML Management"

5/3/07 LEAD Speaker Series; Woodland Hills, CA. "Sprycel (dasatinib)"

5/10/07 LEAD Speaker Series; Santa Barbara, CA. "Sprycel (dasatinib)"

6/4/07 Mealey's Benzene Litigation Conference; Santa Monica, CA. "Update on Benzene Related Blood Disorders"

8/9/07 LEAD Speaker Series; La Habra, CA. "Sprycel (dasatinib)"

8/16-17/07 The Aplastic Anemia & MDS International Foundation, Inc. Annual Patient & Family Conference; Las Vegas, NV. "Scientific Highlights in Bone Marrow Failure", "Roundtable Discussion – Aplastic Anemia", "Future of Research in Bone Marrow Failure"

9/12/07 Continuing Education Regional Symposium; Beverly Hills, CA. "The Future is NOW for the Treatment of Chronic Myelogenous Leukemia"

9/29/07 TORI Research Network Conference; Lake Arrowhead, CA. "Trials for CML, AML and MDS"

10/4/07 Continuing Education Regional Symposium; Anaheim, CA. "The Future is NOW for the Treatment of Chronic Myelogenous Leukemia"

10/18/07 Cedars Sinai Noon Lecture; Beverly Hills, CA. "Update on CML Management"

10/21/07 California Society of Health-System Pharmacists Seminar; Palm Springs, CA. "Myelodysplastic Syndrome"

10/23/07 Educational Dinner Series; Beverly Hills, CA. "Update on CML Management"

11/01/07 Hematology/Oncology Grand Rounds; UCLA Medical Center. "Myelodysplastic Syndrome"

11/08/07 Educational Dinner Series; San Diego, CA. "Update on the Management of CML"

1/11/08 Hematology/Oncology Grand Rounds; UCLA Medical Center. "CML Update"

2/12/08 Educational Dinner Series; Lancaster, CA. "Update on the Management of CML"

3/01/08 Leukemia Team in Training pep talk, Pasadena, CA. "Why You Should Run for the LLS"

5/8/08 Hematology-Oncology Medical Group; Fresno, CA. "Update on CML Management"

Educational Dinner Series; Fresno, CA. "Update on CML Management"

5/22/08 King-Harbor Hospital; Los Angeles, CA. "Update on CML Management"

9/19/08 Hematology/Oncology Grand Rounds; UCLA Medical Center. "Myelodysplastic Syndrome"

10/06/08 New Drugs in Hematology; Bologna, IT. "PHA739358: an Aurora kinase inhibitor with activity against the BCR-ABL kinase"

11/06/08 King-Harbor Hospital; Los Angeles, CA. "An Overview of Treatment with Sprycel"

11/06/08 Ontario, CA. "An Overview of Treatment with Sprycel"

11/20/08 El Segundo, CA. "Advancement of Patient Care in Ph+ CML: A Case-Based Series"

1/26/09 Santa Ana, CA. "Tasigna Development and Clinical Profile in Ph+ CML"

3/05/09 Pathology 270, UCLA Medical Center. "Targeted Therapy for CML"

3/06/09 Orange, CA. "An Overview of Treatment with Sprycel"

4/15/09 Hematopathology Conference, UCLA Medical Center. "Blast Crisis of CML"

4/23/09 Pacific Shores Medical Group, Costa Mesa, CA. "Tasigna Development and Clinical Profile in Ph+ CML"

4/24/09 Inland Hematology/Oncology, San Bernadino, CA. "Tasigna Development and Clinical Profile in Ph+ CML"

4/30/09 Costa Mesa, CA. "Tasigna Development and Clinical Profile in Ph+ CML"

5/08/09 Hematology/Oncology Grand Rounds; UCLA Medical Center. "CML Update"

6/02/09 St. Jude's Comprehensive Cancer Center, Fullerton, CA. "Tasigna Development and Clinical Profile in Ph+ CML"

7/12/09 The Aplastic Anemia & MDS International Foundation, Inc. Annual Patient & Family Conference; Indianapolis, IN. "Research Update of Bone Marrow Failure", "Late Concerns and Complications of Aplastic Anemia"

9/26/09 The Aplastic Anemia & MDS International Foundation, Inc. UCLA Patient & Family Conference: "Living with Myelodysplastic Syndrome"; Los Angeles, CA. "MDS: Why Me?", "Aplastic Anemia Update: Understanding New and Emerging Therapies"

10/21/09 The Leukemia & Lymphoma Society Marshall A. Lichtman Specialized Center of Research Progress Review Meeting; New York, NY. "Molecularly Targeted Therapy for Leukemia"

11/05/09 Fountain Valley Regional Medical Center; Fountain Valley, CA. "Dasatinib (Sprycel): Efficacy and Safety in CML"

11/13/09 LAC/USC Medical Center; Los Angeles, CA. "Tasigna (Nilotinib): Development and Clinical Profile in Ph+ CML"

1/26/10 Leukemia and Lymphoma Society Patient Conference, UCLA Medical Center: "Clinical Trials"

2/19/10 Pacific Shores Medical Group; Torrance, CA. "Clinical Profile of a 2<sup>nd</sup> Option for Ph+ CML "

2/23/10 Pasadena, CA. "Clinical Profile of a 2<sup>nd</sup> Option for Ph+ CML "

3/4/10 Colton, CA. "Clinical Profile of a 2<sup>nd</sup> Option for Ph+ CML "

3/9/10 Torrance Memorial Medical Center, Torrance, CA. "Addressing Primary Resistance and Intolerance to Ph+ CML Therapy"

3/11/10 Costa Mesa, CA. "Clinical Profile of a 2<sup>nd</sup> Option for Ph+ CML "

3/15/10 Torrance, CA. "Clinical Profile of a 2<sup>nd</sup> Option for Ph+ CML "

3/23/10 Pacific Shores Medical Group, Long Beach, CA. "Sprycel –Efficacy and Safety in Chronic Phase CML"

5/25/10 St. Jude Medical Center, Fullerton, CA. "Clinical Profile of a 2<sup>nd</sup> Therapeutic Option for Ph+ CML"

6/8/10 La Jolla, CA. "Addressing Secondary Resistance and Intolerance to Ph+ CML CP Therapy"

10/8/10 Los Angeles, CA. "Treatment Strategies fo Ph+ CML"

10/26/10 Scripps Hospital, La Jolla, CA. "Addressing Secondary Resistance and Intolerance to Ph+ CML CP Therapy"

12/17/10 Torrance, CA. "Addressing Secondary Resistance and Intolerance to Ph+ CML CP Therapy"

6/3/11 Teleconference. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

6/10/11 Orange, CA. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

6/14/11 Teleconference. "Ph+ CML Patient Monitoring"

6/17/11 "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

6/23/11 Hollywood, CA. "Practical Strategies for the Management of CML"

6/27/11 Teleconference. "Ph+ CML Patient Monitoring"

7/12/11 La Jolla, CA. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

7/19/11 Teleconference. "Ph+ CML Patient Monitoring"

8/9/11 Lancaster, CA. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

8/13/11 Teleconference. "Ph+ CML Patient Monitoring"

8/18/11 Teleconference. "Ph+ CML Patient Monitoring"

8/19/11 Torrance, CA. "Ph+ CML Patient Monitoring"

10/24/11 Harbor UCLA Hospital, Torrance, CA. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"

12/11/11 Teleconference. "Ph+ CML Patient Monitoring"

- 12/15/11 Loma Linda, CA. "SPRYCEL: An Option for First Line Treatment of Ph+ CML in Chronic Phase"
- 2012 Pharmaceutical Sponsored Talks:  
BMS: 7 talks about CML and Sprycel  
Incyte: 3 talks about Myelofibrosis and Jakafi  
Novartis: 10 talks about CML and Tasigna
- 1/21/12 Leukemia and Lymphoma Society of America Patient Conference, Los Angeles, CA. "CML Update"
- 4/21/12 The Aplastic Anemia & MDS International Foundation, Inc. UCLA Patient & Family Conference, Los Angeles. "Advances in MDS Treatment; What's on the Horizon".
- 7/6/12 Hematology/Oncology Grand Rounds; UCLA Medical Center. "The Landscape of CML Therapy"
- 2013 Pharmaceutical Sponsored Talks:  
Ariad: 7 talks about CML and Ponatinib  
BMS: 5 talks about CML and Sprycel  
Incyte: 14 talks about Myelofibrosis and Jakafi  
Novartis: 3 talks about CML and Tasigna
- 1/26/13 Leukemia and Lymphoma Society of America Patient Conference, Los Angeles, CA. "CML Update"
- 10/24/13 Leukemia and Lymphoma Society of America Conference, Los Angeles, CA. "Myelofibrosis: New Advances and Treatment"
- 2/15/14 Leukemia and Lymphoma Society of America Patient Conference, Los Angeles, CA. "Update on MDS"
- 2/28/14 Hematology/Oncology Grand Rounds; UCLA Medical Center. "The Classification and Treatment of MDS"
- 8/22/14 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Huntington Beach, CA. "Medical Therapies for Low Risk MDS: Who to Treat, When, and With What"
- 10/28/14 Hematology/Oncology Grand Rounds; UCLA Medical Center. "Treatment Options and Response Monitoring in CML"
- 2014 Pharmaceutical Sponsored Talks:  
BMS: 3 talks about CML and Sprycel  
Incyte: 1 talk about Myelofibrosis and Jakafi
- 2/7/15 Leukemia and Lymphoma Society of America Patient Conference, Los Angeles, CA. "Chronic Myeloid Leukemia"
- 2015 Pharmaceutical Sponsored Talks:  
BMS: 3 talks about CML and Sprycel  
Ariad: 1 talk about CML and Ponatinib

## BIBLIOGRAPHY

### I. Research Papers

#### A. Research Papers - Peer Reviewed

- 1) Ohkata K, **Paquette RL**, Paquette, LA: Interdependence of solvolysis rate and aryl-aryl dihedral angle in a series of 4-biphenyldimethylcarbonyl *p*-nitrobenzoates. J Am Chem Soc 101:6687-6693, 1979

- 2) **Paquette RL**, Zhou JY, Yang YC, Clark SC, Koeffler HP: Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. *Blood* 71:1596-1600, 1988
- 3) **Paquette RL**, Berenson J, Lichtenstein A, McCormick F, Koeffler HP: Oncogenes in multiple myeloma: point mutation of *N-ras*. *Oncogene* 5:1659-1663, 1990
- 4) **Paquette RL**, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP: Mutations of p53 and human papillomavirus infection in cervical carcinoma. *Cancer* 72:1272-1280, 1993
- 5) **Paquette RL**, Landaw EM, Pierre RV, Kahan J, Isaacs G, McCormick F, Koeffler HP: *N-ras* mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. *Blood* 82:590-599, 1993
- 6) Nimer S, **Paquette RL**, Golde D, Ireland P, Young D: A phase I/II study of interleukin-3 in aplastic anemia and myelodysplastic syndrome patients. *Exp. Hematol.* 22:875-880, 1994
- 7) Park DJ, Wilczynski SP, **Paquette RL**, Miller CW, Koeffler HP: p53 mutations in HPV-negative cervical carcinoma. *Oncogene* 9:205-210, 1994
- 8) **Paquette RL**, Meshkinpour A, Rosen PJ: Autoimmune myelofibrosis: a steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. *Medicine* 73(3):145-152, 1994
- 9) **Paquette RL**, Tebyani N, Frane M, Ireland P, Champlin RE, Nimer SD: Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. *Blood* 85:283-290, 1995
- 10) Akashi M, Hachiya M, **Paquette RL**, Osawa Y, Shimizu S, Suzuki G: Irradiation increases manganese superoxide dismutase mRNA levels in human fibroblasts. *J Biol Chem* 270:15864-15869, 1995
- 11) Gordon MS, Nemunaitis J, Hoffman R, **Paquette R**, Rosenfeld C, Manfreda SS, Isaacs G, Nimer S: A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. *Blood* 85(11):3066-3076, 1995
- 12) **Paquette RL**, Minosa MR, Verma MC, Nimer SD, Koeffler HP: An interferon- $\gamma$  activation sequence mediates the transcriptional regulation of the IgG Fc receptor type IC gene by interferon- $\gamma$ . *Molec. Immunol.* 32:841-851, 1995
- 13) **Paquette RL**, Hsu N, Koeffler HP: Analysis of *c-kit* gene integrity in aplastic anemia. *Blood Cells, Molecules, and Diseases* 22:159-168, 1996
- 14) **Paquette RL**, Yoshimura R, Veisoh C, Kunkel L, Gajewski J, Rosen PJ: Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. *Br. J. Haematol.* 96:92-97, 1997
- 15) Schiller G, Lee M, Miller T, Lill M, Mittal-Henkle A, **Paquette R**, Sawyers C, Territo M: Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission. *Leukemia* 11:1533-1539, 1997
- 16) **Paquette RL**, Kuramoto K, Tran L, Sopher G, Nimer SD, Zeldis J: Hepatitis C infection in patients with acquired aplastic anemia. *Am J Hematol* 58:122-126, 1998
- 17) **Paquette RL**, Tran L, Landaw EM: Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft versus host disease prophylaxis. *Bone Marrow Transplantation* 22:351-357, 1998
- 18) **Paquette RL**, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA: Interferon- $\alpha$  and granulocyte/macrophage colony-stimulating factor differentiate peripheral blood mononuclear cells into potent antigen-presenting cells. *J Leukoc Biol* 64:358-367, 1998
- 19) **Paquette RL**, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J: Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. *J Hematotherapy* 7:481-491, 1998
- 20) Schiller G, Lee M, **Paquette R**, Sawyers C, Khoubian F, Territo M: Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. *Leukemia Lymphoma* 33:475-484, 1999
- 21) **Paquette RL**, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Ex vivo expanded unselected peripheral blood progenitor cells reduce post-transplant neutropenia, thrombocytopenia and anemia in breast cancer patients. *Blood* 96:2385-2390, 2000

- 22) Schiller G, Wong S, Lowe T, Snead G, **Paquette R**, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M: Transplantation of IL-2 mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. *Leukemia* 15:757-763, 2001
- 23) Gorre M, Mohammed M, Ellwood K, Hsu N, **Paquette R**, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 293:876-880, 2001
- 24) **Paquette RL**, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. *Exp Hematol* 30(4):374-380, 2002
- 25) Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, T Fischer MD, O'Brien SG, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, **Paquette RL**, Druker BJ: Gleevec (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. *Blood* 99(10):3530-3539, 2002
- 26) Brazier RM, Laudner TM, Druker BJ, Olson S, Magenis E, Mauro MJ, Sawyers CL, **Paquette RL**, Naiem F, Resta DJ, O'Dwyer ME: Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. *Blood* 100(2):435-441, 2002
- 27) **Paquette RL**, Hsu N, Said J, Mohammed M, Rao N, Schiller G, Sawyers C, Glaspy J: Interferon- $\alpha$  induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. *Leukemia* 16(8):1484-1489, 2002
- 28) Shah NP, Nicoll JM, Nagar B, Gorre ME, **Paquette RL**, Kuriyan J, Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* 2:117-125, 2002
- 29) Collisson EA, Lashkari A, Malone R, **Paquette R**, Emmanouilides C, Territo MC, Schiller GJ: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission. *Leukemia* 17:2183-2188, 2003
- 30) O'Farrell AM, Foran J, Fiedler W, Serve H, **Paquette R**, Cooper P, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in AML Patients. *Clin Cancer Res* 9(15):5465-5476, 2003
- 31) Lashkari A, Lowe T, Collisson E, **Paquette R**, Emmanouilides C, Territo M, Schiller: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients  $>$  or  $=$ 60 years with acute myelogenous leukemia. *Biol Blood Marrow Transplant* 12(4):466-71, 2006
- 32) Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, **Paquette R**, Cortes J, O'Brien S, Nicaise L, Bleickardt E, Blackwood-Chirchir, M.A., Iyer V, Chen T, Huang F, Decillis A, Sawyers C.L. Activity of the ABL kinase inhibitor dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. *N Engl J Med* 354(24):2531-41, 2006
- 33) De Angelo DJ, Stone RM, Heaney ML, Nimer SJ, **Paquette RL**, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf J-M, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. *Blood* 108:3674-3681, 2006
- 34) Deininger MW, Cortes J, **Paquette R**, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Reiffers J, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, Sol C, Krahnke T, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. Good prognosis of CML patients with clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. *Cancer* 2007; 110:1509-1519.
- 35) Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, **Paquette RL**, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. *J Clin Invest* 2007;117:2562-2569.



- 36) Lai D, Loughran T Jr, Maciejewski J, Sasu S, Song S, Eppling-Burnette PK, **Paquette RL**. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. *Leukemia Res* 2008;32(5):823-827.
- 37) Pullarkat S, Sedarat F, **Paquette R**, Said J. Systemic mastocytosis with plasma cell dyscrasia: report of a case. *Leukemia Res* 2008;32(7):1160-3
- 38) O'Connell RM, Rao DS, Chaudhuri AA, Boldin M, Taganov K, Nicoll J, **Paquette R**, Baltimore D. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. *J Exp Med* 2008;205(3):585-94
- 39) Porkka K, Koskenvesa P, Lundan T, Rimpilained J, Smykla R, Wild R, Luo F, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Bababulle F, Dombret H, Duarte RF, Elonen E, **Paquette R**, Zwaan CM, Lee FYF. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. *Blood* 2008;112(4):1005-12.
- 40) Gabilove J, **Paquette R**, Lyons RM, Mushtaq C, Sekeres MA, Lam H, Dreiling L. A phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anemia in patients with myelodysplastic syndrome. *Br J Haematol.* 2008;42(3):379-93.
- 41) Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, **Paquette RL**, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. *J Clin Oncol* 2008;26(19):3204-12.
- 42) Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, **Paquette R**, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. *J Natl Cancer Inst.* 2008;100(21):1542-51.
- 43) Mustjoki S, Ekblom M, Almqvist A, Arstila P, Dybedal I, Eveling F, Eppling-Burnette PK, Gedde-Dahl T, Hjorth-Hansen H, Hoglund M, Koivunen E, Koskenvesa P, Kovanen P, Laine J, Laurinoli T, Liesveld J, Lundan T, **Paquette R**, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. *Leukemia* 2009;23(8):1398-405.
- 44) Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, **Paquette RL**, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. *J Clin Oncol.* 2009;27:4563-9.
- 45) Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, **Paquette RL**, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of e3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. *J Clin Oncol* 2009;27:6109-6116.
- 46) **Paquette RL**, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. *Leuk Res.* 2010;34:708-713.
- 47) Porkka K, Khoury HJ, **Paquette RL**, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. *Cancer* 2010;116:377-386.
- 48) Nowak D, Ogawa S, Mischen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, **Paquette R**, Chang MS, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koefler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. *Blood* 2010;115:1049-1053.
- 49) Sekeres MA, List AF, Cuthbertson D, **Paquette R**, Ganetsky R, Latham D, Paulik K, Afaible M, Saba HI, Loughran TP Jr, Maciejewski JP. Phase I combination of lenalidomide and azacytidine in patients with higher-risk myelodysplastic syndromes. *J Clin Oncol.* 2010;28:2253-8
- 50) Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, **Paquette R**, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer.* 2010;116:3852-61.

- 51) Patel S, Said J, Song S, Nishimoto W, **Paquette R**. A case of hemolytic anemia and severe thrombocytopenia related to histiocytic sarcoma. *Leuk Res*. 2010;34:257-258.
- 52) Kantarjian HM, Giles FJ, Greenberg PL, **Paquette RL**, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. *Blood*. 2010;116:3163-70.
- 53) Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, **Paquette R**, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. *Blood*. 2011;117(17):4552-60. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. *Blood*. 2011;117(21):e198-206.
- 54) Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, **Paquette R**, Maciejewski JP. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. *Cancer Res*. 2011;71(12):4183-91.
- 55) Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, Hsi ED, **Paquette RL**, Loughran TP Jr, Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. *Blood* 2011;118:4384-93
- 56) **Paquette RL**, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. *Cancer Genet*. 2011;204(7):392-7.
- 57) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner E, Lyons RM, **Paquette R**, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Ruxolitinib for Myelofibrosis: Results of a Double-Blind, Placebo-Controlled Trial. *N Engl J Med* 2012;366:799-807
- 58) Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbaban NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, **Paquette R**, List AF, Maciejewski JP, Loughran Jr.TP. Seroreactivity to a LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. *Leuk Res* 2012;36:581-7.
- 59) Stone R, Fischer T, **Paquette R**, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian H, DeAngelo DA, Huntsman-Labed A, Dutreix C, Rai S, del Corral A, Giles F. Phase IB Study of Midostaurin, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Younger Newly Diagnosed Adult Patients with Acute Myeloid Leukemia. *Leukemia*. 2012;26:2061-8
- 60) Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, **Paquette R**, Seggewiss-Bernhardt R, Guerri-Bresler A, Talbot A, Cayuela JM, Mahon FX, Porkka K, Lipton J, Partanen J, Rousselot P, Mustjoki S. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. *Exp Hematol*. 2012;40:906-913.
- 61) Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, **Paquette R**, Loughran TP Jr, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. *J Immunol* 2012;189:3198-208.
- 62) Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Aftab M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarrokhi A, Visconte V, Makishima H, Jerez A, **Paquette R**, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndrome. *Blood* 2012 Aug 22 (Epub)
- 63) Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, **Paquette RL**, Loughran TP Jr, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naïve T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. *Leukemia* 2012 Oct 17 (epub).

64) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, **Paquette R**, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. *Br J Haematol.* 2013;161(4):508-16.

65) Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Sauntharajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP. Somatic SETBP1 mutations in myeloid malignancies. *Nat Genet.* 2013;45(8):942-6.

66) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, **Paquette R**, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. *Haematologica.* 2013;98(12):1865-71.

67) Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, **Paquette R**, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med.* 2013;369(19):1783-96.

68) Talpaz M, **Paquette R**, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. *J Hematol Oncol.* 2013;29;6(1):81.

69) Mesa RA, Kiladjan JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, **Paquette R**, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. *Haematologica.* 2014;99(2):292-8.

70) Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, **Paquette R**, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. *Haematologica.* 2014;99(7):1176-83.

## **B. Research Papers - Peer Reviewed (In Press)**

## **C. Research Papers - Peer Reviewed (Submitted)**

1) Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger, MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner EO, Lyons RM, **Paquette R**, Raza A, Jones, Kornacki D, Sun K, Kantarjian H, for the COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from COMFORT-I. *Blood*, submitted.

2) Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, **Paquette R**, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. *Haematologica*, submitted.

## **II Books and Book Chapters**

1) **Paquette RL**, Koeffler HP: Retinoids and 1,25 dihydroxyvitamin D<sub>3</sub>: role in myelodysplastic syndromes and leukemia. In: *Proceedings of International Symposium on Myelodysplastic Syndromes: Pathophysiology and Treatment.* Elsevier Science Publishers, 1988

- 2) **Paquette RL**, Koeffler HP: Myelodysplastic syndrome: culture studies and their implications for therapy. In: The Myelodysplastic Syndromes. Mufti GJ, Galton DAG (ed). Churchill Livingstone, 1992
- 3) Munker R, Hiller E, **Paquette R**: Modern Hematology. Humana Press, 1999
- 4) Munker R, Hiller E, **Paquette R**: Modern Hematology, 2<sup>nd</sup> Edition. Humana Press, 2006
- 5) Schiller G, Casciato DA, **Paquette RL**. Chapter 23. Chronic Leukemias. In: Manual of Clinical Oncology, Sixth Edition. Lippincot Williams & Wilkins, 2009
- 6) **Paquette RL**, Casciato DA. Chapter 24. Myeloproliferative Disorders. In: Manual of Clinical Oncology, Sixth Edition. Lippincot Williams & Wilkins, 2009
- 7) Schiller G, Casciato DA, **Paquette RL**. Chapter 23. Chronic Leukemias. In: Manual of Clinical Oncology, Seventh Edition. Lippincot Williams & Wilkins, 2012
- 8) **Paquette RL**, Casciato DA. Chapter 24. Myeloproliferative Disorders. In: Manual of Clinical Oncology, Sixth Edition. Lippincot Williams & Wilkins, 2012
- 9) Eradat H, **Paquette RL**. Chapter 24. Chronic Leukemias. In: Manual of Clinical Oncology, Eighth Edition. Lippincot Williams & Wilkins, 2016
- 10) **Paquette RL**. Chapter 25. Myeloproliferative Neoplasms. In: Manual of Clinical Oncology, Eighth Edition. Lippincot Williams & Wilkins, 2016

### **Books and Book Chapters**

#### **III     Reviews**

- 1) **Paquette RL**, Koeffler HP: Differentiation therapy. In: Hematology/Oncology Clinics of North America. Myelodysplastic Syndromes. 6(3):687-706, 1992. W. B. Saunders Company
- 2) **Paquette RL**, Glaspy J, Turner RR: Quality of life for the patient with prostate or lung cancer. Veterans Health Systems Journal 3:40-44, 1998
- 3) **Paquette RL**: Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology 9 (Suppl 10):153-161, 2002

#### **IV     Editorials**

- 1) **Paquette R**, Dorshkind K: Optimizing hematopoietic recovery following bone marrow transplantation. J Clin Invest. 109(12):1527-8, 2002
- 2) **Paquette RL**: Reply to letter from C Delfini et al. Leukemia 17:985, 2003
- 3) Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, **Paquette R**, Territo MC: Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 104:1581, 2004.

#### **V     Papers in Preparation**

- 1) **Paquette R**, Mead M, Mohammed H, Shah NP, Sawyers CL. Intermittent Dasatinib Dosing Schedule Preserves Efficacy and Minimizes Toxicity in Chronic Phase CML Patients: Reanalysis of Phase I Data
- 2) Goldberg SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, **Paquette R**, Simonsson B, Zyczynski T, Foreman A, Turner M, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro M. First-line treatment selection and early monitoring in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: the SIMPLICITY study